J Frontier (2934) Fundamentals 2026 — Revenue Analysis | SniperIQ
J Frontier (2934) is a JP-listed Healthcare company in Medical - Distribution with a market capitalization of ¥9.2B, trading at ¥1731.00 on the JPX. This SniperIQ fundamentals page covers J Frontier's valuation, profitability (net margin -1.4%), revenue (¥22.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is J Frontier's market cap?
J Frontier (2934) has a market capitalization of approximately ¥9.2B, trading at ¥1731.00 on the JPX. Market cap moves with the live share price.
What is J Frontier's P/E ratio?
J Frontier's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is J Frontier?
J Frontier runs a net profit margin of -1.4%, a gross margin of 37.6%, and an operating margin of 1.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does J Frontier generate?
J Frontier reported revenue of ¥22.2B for fiscal year 2025, with net income of -¥321M and earnings per share (EPS) of -60.64. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does J Frontier pay a dividend?
J Frontier does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is J Frontier financially healthy?
J Frontier carries a debt-to-equity ratio of 4.32x and a current ratio of 1.07x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is J Frontier a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For J Frontier (2934) the key facts are: market cap ¥9.2B, revenue ¥22.2B, 52-week range 1196-2050. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track J Frontier's full fundamentals live
Get J Frontier's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.